Endocyte, Inc. (ECYT) Receives USAN Approval for Nonproprietary Names of Novel Endocyte Drug Candidates
3/23/2012 10:10:09 AM
WEST LAFAYETTE, Ind., March 22, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the World Health Organization and the United States Adopted Names (USAN) Council have approved the nonproprietary name "vintafolide" (pronounced vin ta foe' lide) for Endocyte's therapeutic drug candidate EC145 and the nonproprietary name of "etarfolatide" (pronounced et" ar foe' la tide) for Endocyte's companion imaging agent EC20. Vintafolide and etarfolatide are currently being evaluated in the Phase 3 PROCEED trial for the treatment of women with folate-receptor positive platinum-resistant ovarian cancer. Etarfolatide is being used to select patients with tumors that over-express folate receptors and who are most likely to benefit from vintafolide therapy. Endocyte intends to file European Marketing Authorisation Applications for both agents based on positive Phase 2 results.
comments powered by